Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594984 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Combination With Irinotecan- Erbitux
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00594984 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 38 participants.
The verdict
NCT00594984, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
- DRUG Brivanib
- DRUG Brivanib Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594984
The ClinicalTrials.gov registry entry for NCT00594984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cetuximab is the first listed.
NCT00594984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594984 about?
NCT00594984 is a clinical study titled "Phase I/II Combination With Irinotecan- Erbitux". Part 1: To define the recommended dose of brivanib that can be safely administered in combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic colorectal cancer (MCRC) Part 2: To compare median duration of progression free survival (PFS)
What is the current status of trial NCT00594984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00594984?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG), Brivanib (DRUG), Brivanib Placebo (DRUG).
Who is sponsoring clinical trial NCT00594984?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.